August 11, 2017 / 1:36 PM / 6 months ago

BRIEF-Sun Pharma says co on track to achieve $300 mln synergies from Ranbaxy deal

Aug 11 (Reuters) - Sun Pharmaceutical Industries Ltd :

* MD Dilip Shanghvi says on track to achieve $300 million synergies from Ranbaxy deal

* MD Dilip Shanghvi says some impact of synergies is being lost due to U.S. Pricing pressure

* MD Dilip Shanghvi says Halol plant remeidation is complete, awaiting U.S. FDA reinspection

* Exec says says price control will have some impact on the industry for the next three quarters

* Exec says immediate term focus is to normalise India business post GST

* Exec says competitive intensity, challenging regulatory environment, price controls will determine growth of India market

* Exec says co in the process of filing tildrakizumab new drug application to U.S. FDA in Q3 2018

* Exec says co expects gradual improvement in ebitda margin reaching about 20-22 percent in H2 2018 Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below